

TOWNSEND & BANTA
INTELLECTUAL PROPERTY LAW & LITIGATION
#50028
SUITE 500
1225 EYE STREET, N.W.
WASHINGTON, D.C. 20005 U.S.A.

TELEPHONE 202-682-4727

FACSIMILE 301-754-6495

*** **FACSIMILE TRANSMISSION COVER SHEET** ***

DATE: February 25, 2002

E.D.T. (U.S.A.)

TO:

FAX NO.: 703-305-7939

Name: Examiner Fernando Prats
Art Unit 1651
U.S. Patent and Trademark Office


FROM:

FAX NO.: 301-754-6495

Name: Donald E. Townsend
TOWNSEND & BANTA
1225 Eye Street, N.W., Suite 500
Washington, D.C. 20005

TOTAL NUMBER OF SHEETS INCLUDING THIS PAGE: 9

Comments: Pursuant to our discussion of 2/25/02, enclosed is a copy of a response mailed on February 11, 2002. I would appreciate your consideration of this response.
I hereby certify that this correspondence is being transmitted by facsimile to the U.S. PTO at 703-305-7939 and addressed to the attention of Examiner Fernando Prats at Art Unit 1651 on February 25, 2002.



IF YOU DO NOT RECEIVE ALL SHEETS, PLEASE CALL (301) 681-5948.

**** CONFIDENTIALITY NOTE ****

The documents accompanying this telecopy transmission contain information from the Law Offices of Townsend & Banta, which is confidential or privileged. The information is intended to be for the use by the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this telecopied information is prohibited. If you have received this telecopy in error, please notify us by telephone immediately.

SERIAL NO.: 09/147,237

GROUP: 1651

FILED: April 20, 1999

EXAMINER: F. Prats

TITLE: Immunopotentiators

THE COMMISSIONER OF PATENTS
AND TRADEMARKS
WASHINGTON, D.C. 20231

SIR:

TRANSMITTED HERewith IS AN ☐ AMENDMENT, ☐ REPLY, ☒ RESPONSE AFTER FINAL REJECTION IN THE ABOVE-IDENTIFIED APPLICATION.

☐ Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.

☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

☒ No additional fee is required.

THE FEE HAS BEEN CALCULATED AS SHOWN BELOW:

CLAIMS	REMAINING AFTER AMENDMENT		HIGH.# PREV. PAID FOR	PRESENT EXTRA	SMALL ENTITY RATE ADD'L FEE	OTHER THAN A SMALL ENTITY RATE ADD'L FEE
TOTAL	7	MINUS	20	= 0	X9=\$	X18=\$0
INDEP.	2	MINUS	3	= 0	X42=\$	X84=\$0

<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		+140=\$	+280=\$
	TOTAL ADD'L FEE		-0-


☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 20-1424. A duplicate copy of this sheet is attached.

- ☒ Any additional filing fees under 37 C.F.R. 1.16 for the presentation of extra claims.
☒ Any patent application processing fees under 37 C.F.R. 1.17.
☒ Any extensions of time under 37 C.F.R. 1.17.

☐ Please charge my deposit account No. 20-1424 in the amount of \$

☐ A check in the amount \$ -0- is attached.

Date: February 11, 2002


Donald E. Townsend
Attorney of Record
Registration No. 22.069

TOWNSEND & BANTA
1225 Eye Street, N.W.
Suite 500, #50028
Washington, D.C. 20005
(202) 682-4727

DOCKET NO. TOS-123-USA-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
E. YAGI, et al.

Serial No.: 09/147,237

Art Unit: 1651

Filed: April 20, 1999

Examiner: F. Prats

For: Immunopotentiators

RESPONSE AFTER FINAL REJECTION

NON-FEE AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Responsive to the official final Office Action mailed December 10, 2001, in the matter of the above-identified application, applicant hereby responds as follows:

REMARKS

Reconsideration is respectfully requested of the rejection of Claims 1-4 and 15-17 under 35 U.S.C. § 102(b) as being anticipated by N'Guyen, et al., U.S. Patent 5,023,235.

Applicants hereby traverse the final rejection of Claims 1-4 and 15-17 on N'Guyen on the ground that the final rejection is contrary to a number of well settled principles of patent law. Each of these principles and the proper application of the law in this case is discussed hereinafter as follows:

The first issue presented is whether the N'Guyen reference is considered as a whole in the final rejection. Applicants respectfully submit that the answer is in the negative because the final rejection completely disregards major portions of the N'Guyen

DOCKET NO. TOS-123-USA-C

CERTIFICATE OF MAILING

I hereby certify that this response and transmittal in Docket No. TOS-123-USA-C, Serial No. 09/147,237 is being deposited with the

United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C 20231

on February 11, 2002.

Donald E. Townsend

